CTOs on the Move

Health Fuse

www.healthfuse.com

 
Health Fuse is a Milwaukee, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 5K-10K
  • Annual Revenue: $250-500 Million

Executives

Name Title Contact Details

Similar Companies

Intervet/ Schering-Plough Animal Health

Intervet/ Schering-Plough Animal Health is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Xagenic

Xagenic is a molecular diagnostics company developing a true point- of-care platform. Our aim is to enable on-demand, near patient molecular testing, empowering clinicians in making treatment decisions for their patients at the time of first consultation. This will dramatically improve patient care and reduce health care costs.

Sharon Regional Health System

As a major provider of advanced health and medical services for more than 100 years, Sharon Regional is a major resource for the northwest Pennsylvania-northeast Ohio region.

Informatics Outsourcing

Informatics Outsourcing is a Santa Clara, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neurotrope Inc

Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage.  Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions.  These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization.  In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.